For patients with cisplatin-ineligible bladder cancer, presurgical Padcev decreased the cancer stage without leading to delays in surgery. Neoadjuvant (presurgical) Padcev (enfortumab vedotin) had ...
In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease ...
(RTTNews) - Pfizer Inc. (PFE) and Astellas Pharma Inc. (ALPMY, 4503.T) announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (enfortumab vedotin-ejfv), a Nectin-4 directed ...
The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the treatment of bladder cancer. The PD-1/antibody-drug conjugate pairing ...
A combination of Pfizer and Astellas’ Padcev (enfortumab vedotin) and MSD’s Keytruda (pembrolizumab) has offered significant improvements to patient outcomes compared with standard of care (SoC) ...
The combination of Padcev and Keytruda has once again delivered strong results, this time significantly improving overall survival (OS) for patients with cisplatin-eligible muscle-invasive bladder ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results